The purpose of this 6-week, double-blind, placebo-controlled, crossover study is to explore
new treatment options for people with depression who have high inflammation and anhedonia.
Thirty-five male and female participants with depression, between the ages of 25-55 years of
age, will be randomized to two study tracks (A and B) to receive both placebo and three doses
of L-DOPA, given in different orders. Increases or decreases in each dose will occur
gradually over 6 weeks of the study. Participants will complete lab tests, medical and
psychiatric assessments, neurocognitive testing and functional MRI (fMRI) scans as part of
the study. The total length of participation is about 2 months.
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa